Network Version
Purmorphamine Data Sheet
| Product Name: | Purmorphamine |
 |
|---|---|---|
| CAS No.: | 483367-10-8 | |
| Cat. No.: | HY-15108 | |
| MWt: | 520.62 | |
| Formula: | C31H32N6O2 | |
| Purity : | >98% | |
| Solubility: | DMSO : 33.33 mg/mL (64.02 mM; Need ultrasonic) | |
| Mechanisms: | Target: Cancer Neurological Disease | |
| Biological Activity: | ||
| Purmorphamine is a smoothened/Smo receptor agonist with an EC50 of 1 μM. IC50 & Target: IC50: 1.5 μM (Smoothened) In Vitro: Purmorphamine (10, 20 μM) in combination with sirolimus significantly decreases cell numbers according to the MTT assay. Purmorphamine induces up-regulation of alkaline phosphatase activity and expression of RUNX-2 at day 14. Up-regulation of osteocalcin is detected at the 3 and 5 μM doses of purmorphamine on day 14 post-induction. Matrix mineralization remains unchanged in the presence or absence of purmorphamine[1]. Purmorphamine induces STAT3 phosphorylation in mouse ES cell line ES14 and mesenchymal stem cell line C3H10T1/2[2]. Purmorphamine up-regulates the expressionof markers of the osteoblast phenotype-ALP activity and bone-like nodule formationd-in human bonemarrow mesenchymal cells[3]. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com